Compare Summit Therapeutics Inc (SMMT) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Xylem, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Xylem, Inc. trades at $103 (market cap $23.81B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.69% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Xylem, Inc. for 50 Days on average.
| SMMT | XYL | |
|---|---|---|
Market Cap | $13.71B | $23.81B |
Volume | 6,173,057 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $26.38 | $152.95 |
52-Week Low | $12.43 | $100.92 |
Typical Hold Time | 16 Days | 50 Days |
Enterprise Value | $13.04B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
XYL trades at $102.71, up 0.86% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $9.04B in 2025 with a net income margin of 10.59%, and has beaten EPS estimates in recent quarters. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, and the appointment of a new CFO.
Outlook is supported by strong water-solutions demand and margin expansion, but risks include China weakness and higher debt. Analysts are mixed with a consensus price target of $149.13, implying significant upside from current levels, though near-term technical pressure may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
